Immunomodulatory Role and Therapeutic Potential of HLA-DR+ Regulatory T Cells in Systemic Lupus Erythematosus

被引：0
作者：
Zhang, Jing [1 ]
Liao, Bei [1 ]
Wang, Xiaobing [1 ]
Liu, Weijun [1 ]
机构：
[1] Nanchang Univ, Candidate Branch Natl Clin Res Ctr Skin Dis, JXHC Key Lab Skin Infect & Immun, Affiliated Dermatol Hosp,Dermatol Hosp Jiangxi Pro, 388 Yingbingbei Rd, Nanchang 330003, Jiangxi, Peoples R China
来源：
IMMUNOLOGICAL INVESTIGATIONS | 2025年
关键词：
HLA-DR+ regulatory T cells; immune tolerance; systemic lupus erythematosus; ACTIVATION; EXPRESSION; RISK; TREG;
D O I：
10.1080/08820139.2025.2475816
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Background Systemic lupus erythematosus (SLE) is a complex autoimmune disease that affects multiple organ systems. A key element in maintaining immune tolerance and preventing autoimmunity is the role of regulatory T cells (Treg cells). Among these, HLA-DR+ Treg cells represent a distinct subset, and their altered expression and functionality in SLE are closely associated with the progression of the disease. This review explores the biological characteristics of HLA-DR+ Treg cells, their mechanisms of action in SLE, as well as their potential and the challenges they pose as therapeutic targets. Methods and results This review offers a comprehensive analysis of the mechanisms by which HLA-DR+ Treg cells regulate immune responses. It highlights their direct interactions with autoreactive T cells and antigen-presenting cells, which contribute to the suppression of autoimmunity. Additionally, the review explores the critical role of these cells in maintaining immune tolerance and their promising potential in the context of antigen-specific immunotherapy. Discussion The potential of HLA-DR+ Treg cells in the treatment of systemic lupus erythematosus (SLE) is considerable, particularly due to their capacity to generate antigen-specific Tregs. The development of Treg-based therapies, including the expansion of both polyclonal and antigen-specific Tregs, is an area of active investigation. Nonetheless, several challenges persist, such as the need to optimize protocols for Treg generation and expansion, ensure the stability of the Treg phenotype, and address potential safety concerns associated with cellular therapies.Continued research is essential to fully harness the potential of HLA-DR+ Treg cells in the treatment of SLE and other autoimmune diseases.
引用
收藏
页数：18
相关论文
共 94 条
  • [21] Doglio M., Ugolini A., Bercher-Brayer C., Camisa B., Toma C., Norata R., Del Rosso S., Greco R., Ciceri F., Sanvito F., Casucci M., Manfredi A.A., Bonini C., Regulatory T cells expressing CD19-targeted chimeric antigen receptor restore homeostasis in systemic lupus erythematosus, Nature Communications, 15, 1, (2024)
  • [22] Eggenhuizen P.J., Cheong R.M.Y., Lo C., Chang J., Ng B.H., Ting Y.T., Monk J.A., Loh K.L., Broury A., Tay E.S.V., Shen C., Zhong Y., Lim S., Chung J.X., Kandane-Rathnayake R., Koelmeyer R., Hoi A., Chaudhry A., Morand E.F., Smith-specific regulatory T cells halt the progression of lupus nephritis, Nature Communications, 15, 1, (2024)
  • [23] Eriksson P., Wallin P., Sjowall C., Clinical experience of sirolimus regarding efficacy and safety in systemic lupus erythematosus, Frontiers in Pharmacology, 10, (2019)
  • [24] Fanouriakis A., Bertsias G., Boumpas D.T., Response to: Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by Fanouriakis, Annals of the Rheumatic Diseases, 83, 11, (2024)
  • [25] Fanouriakis A., Kostopoulou M., Bertsias G., Boumpas D.T., Response to: Correspondence on ‘EULAR recommendations for the management of systemic lupus erythematosus: 2023 update’ by fanouriakis et al, Annals of the Rheumatic Diseases, 83, 10, (2023)
  • [26] Furie R.A., Bruce I.N., Dorner T., Leon M.G., Leszczynski P., Urowitz M., Haier B., Jimenez T., Brittain C., Liu J., Barbey C., Stach C., Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus, Rheumatology (Oxford), 60, 11, pp. 5397-5407, (2021)
  • [27] Gootjes C., Zwaginga J.J., Roep B.O., Nikolic T., Defining human regulatory T cells beyond FOXP3: The need to combine phenotype with function, Cells, 13, 11, (2024)
  • [28] Gordon C., Amissah-Arthur M.B., Gayed M., Brown S., Bruce I.N., D'Cruz D., Empson B., Griffiths B., Jayne D., Khamashta M., Lightstone L., Norton P., Norton Y., Schreiber K., Isenberg D., The British society for rheumatology guideline for the management of systemic lupus erythematosus in adults, Rheumatology (Oxford), 57, 1, pp. e1-e45, (2018)
  • [29] Gubic S., Toplak Z., Sterle M., Peigneur S., Tomasic T., Pardo L.A., Tytgat J., Zega A., Masic L.P., Discovery of K V 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges, Medicinal Research Reviews, 41, 4, pp. 2423-2473, (2021)
  • [30] Hagen M., Muller F., Wirsching A., Kharboutli S., Sporl S., Aigner M., Volkl S., Kohler B., Dorfler A., Grieshaber-Bouyer R., Mackensen A., Schett G., Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells, Lancet, 404, pp. 2158-2160, (2024)
12345678910